The investigators constructed an anti-CD30 CAR-T cell designated to treat r/r Hodgkin lymphoma and cutaneous T-cell lymphoma (CTCL) that incorporates C-C chemokine receptor type 4 (CCR4) (47). Here, TNFRSF8 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.